Viatris (VTRS) Competitors

Viatris (NASDAQ:VTRS) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

Do analysts rate VTRS or PFE?

Viatris presently has a consensus price target of $10.40, indicating a potential upside of 12.43%. Pfizer has a consensus price target of $28.55, indicating a potential upside of 10.80%. Given Viatris' higher possible upside, research analysts plainly believe Viatris is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Pfizer	1 Sell rating(s)	13 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.45

Does the media refer more to VTRS or PFE?

In the previous week, Pfizer had 108 more articles in the media than Viatris. MarketBeat recorded 110 mentions for Pfizer and 2 mentions for Viatris. Pfizer's average media sentiment score of 0.88 beat Viatris' score of 0.50 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pfizer	56 Very Positive mention(s)	15 Positive mention(s)	27 Neutral mention(s)	4 Negative mention(s)	5 Very Negative mention(s)	Positive

Which has more risk & volatility, VTRS or PFE?

Viatris has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.

Which has better earnings and valuation, VTRS or PFE?

Pfizer has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.74B	0.74	-$634.20M	-$3.17	-2.92
Pfizer	$62.46B	2.35	$8.03B	$1.38	18.67

Is VTRS or PFE a better dividend stock?

Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 5.2%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.7%. Viatris pays out -15.1% of its earnings in the form of a dividend. Pfizer pays out 124.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Is VTRS or PFE more profitable?

Pfizer has a net margin of 12.62% compared to Viatris' net margin of -26.45%. Pfizer's return on equity of 20.33% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-26.45%	16.20%	7.01%
Pfizer	12.62%	20.33%	8.53%

Do insiders & institutionals believe in VTRS or PFE?

79.9% of Viatris shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 0.1% of Viatris shares are held by insiders. Comparatively, 0.1% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Pfizer beats Viatris on 15 of the 20 factors compared between the two stocks.